MedTrace Logo

PERTH 2: Co-design of a Home-based Monitoring Service for Cancer Patients to Optimize Delivery of Systemic Therapy.

NCT03923296 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2022-04-06

No results posted yet for this study

Summary

Iterative co-design study where patients receiving systemic cancer therapy, carers and healthcare professionals involved in delivering cancer therapy, work with Entia to design a home based blood monitoring service. The iterative process means that at each stage of the development process, Entia will be building on what is learnt in the previous stage.

Conditions

Interventions

DEVICE

Blood measurement and monitoring

Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.

BEHAVIORAL

Interviews

Focus group interviews

Sponsors & Collaborators

  • Entia Ltd

    lead INDUSTRY

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2021-07-16
Completion
2021-07-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923296 on ClinicalTrials.gov